Similar companies
Income Statement (USD)
Q3 '24 | QoQ | |
---|---|---|
Revenue | 24M | 8.5% |
Gross Profit | -7.6M | 6.6% |
Cost of Revenue | 32M | 8.1% |
Operating expense | 74M | 9% |
Net Income | -60M | 12.5% |
EBITDA | -58M | 11.8% |
Balance Sheet (USD)
Q3 '24 | QoQ | |
---|---|---|
Total Assets | 519M | 8.8% |
Total Liabilities | 218M | 1.5% |
Total Equity | 301M | 13.5% |
Shares Outstanding | 50M | 0.4% |
Cash Flow (USD)
Q3 '24 | QoQ | |
---|---|---|
Cash from operations | -41M | 10.9% |
Cash from investing | 50M | 18853% |
Cash from financing | -11M | 14.9% |
EPS
Financial Highlights for Regenxbio in Q3 '24
Regenxbio reported a revenue of 24M, which is a 8.5% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at -7.6M, marking a -6.6% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 32M, a 8.1% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 74M, showing a 9% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -60M, showing a -12.5% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -58M, showing a -11.8% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
Regenxbio faced some challenges this quarter with a decline in one or more of the key metrics: revenue, gross profit, or net income. Higher operating expenses might indicate increased investments or potential inefficiencies. A decline in EBITDA signals potential operational challenges or increased costs.